United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $517.05, for a total transaction of $4,291,515.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares in the company, valued at $23,356,182.60. This represents a 15.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $532.94 on Friday. The company has a fifty day moving average of $539.78 and a two-hundred day moving average of $534.19. The stock has a market capitalization of $22.62 billion, a PE ratio of 19.07, a P/E/G ratio of 1.74 and a beta of 0.59. United Therapeutics Corporation has a fifty-two week low of $292.34 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same period last year, the firm posted $6.41 earnings per share. The company’s revenue was down 1.9% compared to the same quarter last year. Research analysts forecast that United Therapeutics Corporation will post 26.65 earnings per share for the current year.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Quarterly EPS exceeded expectations. United Therapeutics reported second-quarter earnings of $7.27 per share, above the approximately $6.82–$6.86 consensus and up from $6.41 a year earlier. Strong profitability, including a net margin above 40%, provides a supportive fundamental backdrop. United Therapeutics Q2 Earnings Surpass Estimates
• Positive Sentiment: Ralinepag remains a major potential catalyst. Management highlighted the submission of regulatory applications for ralinepag, while the Phase 3 program and other pipeline developments could diversify growth beyond the company’s established pulmonary hypertension products. Analysts view these milestones as helping offset near-term competitive pressure on Tyvaso. EPS Strength and Ralinepag’s Phase 3 Milestone
• Positive Sentiment: Analysts remain constructive. H.C. Wainwright reiterated a Buy rating with a $660 target, while RBC maintained Outperform despite lowering its target from $704 to $677. The revised RBC target still implies substantial upside based on the quoted market price. Buy Rating Reiterated on United Therapeutics
• Neutral Sentiment: Revenue missed expectations. Second-quarter revenue declined roughly 2% year over year to $783.3 million, below the $804.65 million analyst estimate. The shortfall reflects near-term pressure despite the EPS beat and pipeline progress. United Therapeutics Reports Second-Quarter Results
• Negative Sentiment: Executives disclosed sizable stock sales. CEO Martine Rothblatt sold 9,500 shares for approximately $4.9 million, and EVP Paul Mahon sold 8,300 shares for about $4.3 million. Although these transactions may be scheduled or personal, they represent reductions in insider ownership and can weigh on sentiment.

Wall Street Analyst Weigh In

UTHR has been the topic of several research analyst reports. JPMorgan Chase & Co. lifted their price objective on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Raymond James Financial initiated coverage on United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price for the company. Bank of America decreased their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Weiss Ratings lowered United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, July 31st. Finally, Morgan Stanley set a $515.00 price target on United Therapeutics in a research report on Thursday. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $646.00.

Institutional Trading of United Therapeutics

Hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP boosted its position in shares of United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after acquiring an additional 1,042,711 shares during the last quarter. Norges Bank acquired a new stake in United Therapeutics during the fourth quarter worth about $293,418,000. Avoro Capital Advisors LLC raised its stake in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares during the period. Janus Henderson Group PLC raised its stake in United Therapeutics by 75.1% during the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after purchasing an additional 341,383 shares during the period. Finally, Baillie Gifford & Co. acquired a new position in United Therapeutics in the 4th quarter valued at about $157,390,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.